Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 44


Uptake, time course, and predictors of risk-reducing surgeries in BRCA carriers.

Beattie MS, Crawford B, Lin F, Vittinghoff E, Ziegler J.

Genet Test Mol Biomarkers. 2009 Feb;13(1):51-6. doi: 10.1089/gtmb.2008.0067.


Precursors to pelvic serous carcinoma and their clinical implications.

Folkins AK, Jarboe EA, Roh MH, Crum CP.

Gynecol Oncol. 2009 Jun;113(3):391-6. doi: 10.1016/j.ygyno.2009.01.013. Epub 2009 Feb 23. Review.


Reproductive and hormonal factors, and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers: results from the International BRCA1/2 Carrier Cohort Study.

Antoniou AC, Rookus M, Andrieu N, Brohet R, Chang-Claude J, Peock S, Cook M, Evans DG, Eeles R; EMBRACE., Nogues C, Faivre L, Gesta P; GENEPSO., van Leeuwen FE, Ausems MG, Osorio A; GEO-HEBON., Caldes T, Simard J, Lubinski J, Gerdes AM, Olah E, F├╝rhauser C, Olsson H, Arver B, Radice P, Easton DF, Goldgar DE.

Cancer Epidemiol Biomarkers Prev. 2009 Feb;18(2):601-10. doi: 10.1158/1055-9965.EPI-08-0546. Epub 2009 Feb 3.


Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers.

Rebbeck TR, Kauff ND, Domchek SM.

J Natl Cancer Inst. 2009 Jan 21;101(2):80-7. doi: 10.1093/jnci/djn442. Epub 2009 Jan 13.


Hormone therapy and the risk of breast cancer in BRCA1 mutation carriers.

Eisen A, Lubinski J, Gronwald J, Moller P, Lynch HT, Klijn J, Kim-Sing C, Neuhausen SL, Gilbert L, Ghadirian P, Manoukian S, Rennert G, Friedman E, Isaacs C, Rosen E, Rosen B, Daly M, Sun P, Narod SA; Hereditary Breast Cancer Clinical Study Group..

J Natl Cancer Inst. 2008 Oct 1;100(19):1361-7. doi: 10.1093/jnci/djn313. Epub 2008 Sep 23.


Talc use, variants of the GSTM1, GSTT1, and NAT2 genes, and risk of epithelial ovarian cancer.

Gates MA, Tworoger SS, Terry KL, Titus-Ernstoff L, Rosner B, De Vivo I, Cramer DW, Hankinson SE.

Cancer Epidemiol Biomarkers Prev. 2008 Sep;17(9):2436-44. doi: 10.1158/1055-9965.EPI-08-0399.


Serous tubal intraepithelial carcinoma: its potential role in primary peritoneal serous carcinoma and serous cancer prevention.

Carlson JW, Miron A, Jarboe EA, Parast MM, Hirsch MS, Lee Y, Muto MG, Kindelberger D, Crum CP.

J Clin Oncol. 2008 Sep 1;26(25):4160-5. doi: 10.1200/JCO.2008.16.4814.


Concise handbook of familial cancer susceptibility syndromes - second edition.

Lindor NM, McMaster ML, Lindor CJ, Greene MH; National Cancer Institute, Division of Cancer Prevention, Community Oncology and Prevention Trials Research Group..

J Natl Cancer Inst Monogr. 2008;(38):1-93. doi: 10.1093/jncimonographs/lgn001. No abstract available.


A prospective study of risk-reducing salpingo-oophorectomy and longitudinal CA-125 screening among women at increased genetic risk of ovarian cancer: design and baseline characteristics: a Gynecologic Oncology Group study.

Greene MH, Piedmonte M, Alberts D, Gail M, Hensley M, Miner Z, Mai PL, Loud J, Rodriguez G, Basil J, Boggess J, Schwartz PE, Kelley JL, Wakeley KE, Minasian L, Skates S.

Cancer Epidemiol Biomarkers Prev. 2008 Mar;17(3):594-604. doi: 10.1158/1055-9965.EPI-07-2703.


A candidate precursor to pelvic serous cancer (p53 signature) and its prevalence in ovaries and fallopian tubes from women with BRCA mutations.

Folkins AK, Jarboe EA, Saleemuddin A, Lee Y, Callahan MJ, Drapkin R, Garber JE, Muto MG, Tworoger S, Crum CP.

Gynecol Oncol. 2008 May;109(2):168-73. doi: 10.1016/j.ygyno.2008.01.012. Epub 2008 Mar 14.


Perineal talc use and ovarian cancer: a critical review.

Muscat JE, Huncharek MS.

Eur J Cancer Prev. 2008 Apr;17(2):139-46. doi: 10.1097/CEJ.0b013e32811080ef. Review.


International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers.

Metcalfe KA, Birenbaum-Carmeli D, Lubinski J, Gronwald J, Lynch H, Moller P, Ghadirian P, Foulkes WD, Klijn J, Friedman E, Kim-Sing C, Ainsworth P, Rosen B, Domchek S, Wagner T, Tung N, Manoukian S, Couch F, Sun P, Narod SA; Hereditary Breast Cancer Clinical Study Group..

Int J Cancer. 2008 May 1;122(9):2017-22. doi: 10.1002/ijc.23340.


Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction.

Callahan MJ, Crum CP, Medeiros F, Kindelberger DW, Elvin JA, Garber JE, Feltmate CM, Berkowitz RS, Muto MG.

J Clin Oncol. 2007 Sep 1;25(25):3985-90.


Association of oral contraceptive use, other contraceptive methods, and infertility with ovarian cancer risk.

Tworoger SS, Fairfield KM, Colditz GA, Rosner BA, Hankinson SE.

Am J Epidemiol. 2007 Oct 15;166(8):894-901. Epub 2007 Jul 26.


Meta-analysis of BRCA1 and BRCA2 penetrance.

Chen S, Parmigiani G.

J Clin Oncol. 2007 Apr 10;25(11):1329-33.


Prophylactic salpingo-oophorectomy in a series of 89 women carrying a BRCA1 or a BRCA2 mutation.

Laki F, Kirova YM, This P, Plancher C, Asselain B, Sastre X, Stoppa-Lyonnet D, Salmon R; IC-BOCRSG IC-BOCRSG: Institut Curie - Breast Ovary Cancer Risk Study Group..

Cancer. 2007 May 1;109(9):1784-90.


Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: Evidence for a causal relationship.

Kindelberger DW, Lee Y, Miron A, Hirsch MS, Feltmate C, Medeiros F, Callahan MJ, Garner EO, Gordon RW, Birch C, Berkowitz RS, Muto MG, Crum CP.

Am J Surg Pathol. 2007 Feb;31(2):161-9.


Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study.

McLaughlin JR, Risch HA, Lubinski J, Moller P, Ghadirian P, Lynch H, Karlan B, Fishman D, Rosen B, Neuhausen SL, Offit K, Kauff N, Domchek S, Tung N, Friedman E, Foulkes W, Sun P, Narod SA; Hereditary Ovarian Cancer Clinical Study Group..

Lancet Oncol. 2007 Jan;8(1):26-34.


Prophylactic bilateral salpingo-oophorectomy compared with surveillance in women with BRCA mutations.

Schmeler KM, Sun CC, Bodurka DC, White KG, Soliman PT, Uyei AR, Erlichman JL, Arun BK, Daniels MS, Rimes SA, Peterson SK, Slomovitz BM, Milam MR, Gershenson DM, Lu KH.

Obstet Gynecol. 2006 Sep;108(3 Pt 1):515-20.


Supplemental Content

Support Center